On Friday, Prime Medicine Inc (NASDAQ: PRME) opened lower -0.30% from the last session, before settling in for the closing price of $3.30. Price fluctuations for PRME have ranged from $2.85 to $9.86 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -25.00% annually for the last half of the decade. Company’s average yearly earnings per share was noted 22.72% at the time writing. With a float of $50.89 million, this company’s outstanding shares have now reached $97.38 million.
In an organization with 234 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.47%, operating margin of -586.63%, and the pretax margin is -568.39%.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Prime Medicine Inc is 61.20%, while institutional ownership is 36.05%. The most recent insider transaction that took place on Feb 15 ’24, was worth 20,000,000. In this transaction Director of this company bought 3,200,000 shares at a rate of $6.25, taking the stock ownership to the 3,200,000 shares. Before that another transaction happened on Feb 15 ’24, when Company’s 10% Owner bought 3,200,000 for $6.25, making the entire transaction worth $20,000,000. This insider now owns 3,200,000 shares in total.
Prime Medicine Inc (PRME) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 22.72% per share during the next fiscal year.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Check out the current performance indicators for Prime Medicine Inc (PRME). In the past quarter, the stock posted a quick ratio of 6.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 537.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.31 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Let’s dig in a bit further. During the last 5-days, its volume was 1.28 million. That was better than the volume of 0.99 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 61.04%. Additionally, its Average True Range was 0.28.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 11.28%, which indicates a significant decrease from 23.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.92% in the past 14 days, which was lower than the 83.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.74, while its 200-day Moving Average is $5.38. However, in the short run, Prime Medicine Inc’s stock first resistance to watch stands at $3.37. Second resistance stands at $3.46. The third major resistance level sits at $3.51. If the price goes on to break the first support level at $3.24, it is likely to go to the next support level at $3.19. The third support level lies at $3.10 if the price breaches the second support level.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are currently 131,161K shares outstanding in the company with a market cap of 430.21 million. Presently, the company’s annual sales total 0 K according to its annual income of -198,130 K. Last quarter, the company’s sales amounted to 210 K and its income totaled -52,520 K.
